Black Diamond Therapeutics (NASDAQ:BDTX) Announces Quarterly Earnings Results

Black Diamond Therapeutics (NASDAQ:BDTX) posted its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.09, Zacks reports.

Black Diamond Therapeutics Stock Performance

Shares of NASDAQ:BDTX traded up $0.08 during trading on Friday, hitting $3.26. The company’s stock had a trading volume of 327,447 shares, compared to its average volume of 818,275. The company has a market capitalization of $184.22 million, a PE ratio of -2.12 and a beta of 2.51. Black Diamond Therapeutics has a fifty-two week low of $1.62 and a fifty-two week high of $7.66. The business has a 50 day moving average price of $4.15 and a two-hundred day moving average price of $5.01.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on BDTX shares. Raymond James began coverage on Black Diamond Therapeutics in a report on Wednesday, July 31st. They set an “outperform” rating and a $20.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $16.00 target price on shares of Black Diamond Therapeutics in a report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a report on Wednesday. Finally, Piper Sandler increased their target price on Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, September 23rd.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.